AXS-12 reboxetine Updated Aug 17
Watch for FDA communications ahead of the May 1, 2027 PDUFA, e.g., any newly scheduled advisory committee, labeling discussions, or a potential priority-review/timing change, and treat AXS-12 approval as incremental upside on top of the AUVELITY (incl. Alzheimer's agitation) and SUNOSI commercial story rather than the stock's primary thesis. Near-term share moves are more likely tied to quarterly product sales and the Alzheimer's agitation launch than to AXS-12, since its binary is ~9 months out.
- NDA accepted and FDA set a PDUFA target action date of May 1, 2027, with no advisory committee meeting currently planned, less regulatory-uncertainty risk.
- AXS-12 has FDA Orphan Drug designation for narcolepsy, which can bring 7-year US exclusivity if approved.
- Completed Phase 3 (NCT05059223, ~90 patients) and Phase 2 CONCERT (NCT03881852) plus decades of prior human use as an antidepressant reduce the 'new mechanism safety surprise' risk.
- The PDUFA is ~8.5 months away (May 1, 2027), a distant binary with FDA refusal-to-file/CRL risk in between; the stock already ran up ~97.7% over 12 months.
- Reboxetine is an old drug: it had generic competition and a mixed commercial/efficacy record as an antidepressant, so Axsome must differentiate it against entrenched narcolepsy treatments (e.g., oxybates, pitolisant) for a niche cataplexy population (context; not from web sources this session).
- Insider selling: CEO Herriot Tabuteau sold ~$9.5M of stock on Aug 5, 2026 at $212.01 and ~$1.0M on Aug 6 at $213.95 (10b5-1 flagged).